Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper.
AllergyMonitor®
MASK‐air®
allergen immunotherapy
allergy
digital biomarkers
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
revised:
05
04
2024
received:
06
03
2024
accepted:
12
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person-centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision-making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried-over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)-Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)-on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally-enabled PCC in AIT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Academy of Allergy and Clinical Immunology (EAACI)
Organisme : EU Horizon project SYLVA
ID : 101086109
Informations de copyright
© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
IAoPO. The global voice for patient‐centred healthcare. Accessed March 28, 2024. https://www.iapo.org.uk
American Geriatrics Society Expert Panel on Person‐Centered Care. Person‐centered care: a definition and essential elements. J Am Geriatr Soc. 2016;64(1):15‐18.
Hakansson Eklund J, Holmstrom IK, Kumlin T, et al. “Same same or different?” A review of reviews of person‐centered and patient‐centered care. Patient Educ Couns. 2019;102(1):3‐11.
Rosengren K, Brannefors P, Carlstrom E. Adoption of the concept of person‐centred care into discourse in Europe: a systematic literature review. J Health Organ Manag. 2021;35(9):265‐280.
OECD. Integrating Care to Prevent and Manage Chronic Diseases: Best Practices in Public Health. OECD Publishing; 2023.
Bousquet J, Sousa‐Pinto B, Anto JM, et al. MASK‐air(R): an OECD (Organisation for Economic Coordination and Development) best practice for public health on integrated care for chronic diseases. J Allergy Clin Immunol Pract. 2024. Online ahead of print. doi:10.1016/j.jaip.2024.03.024
Granstrom E, Wannheden C, Brommels M, Hvitfeldt H, Nystrom ME. Digital tools as promoters for person‐centered care practices in chronic care? Healthcare professionals' experiences from rheumatology care. BMC Health Serv Res. 2020;20(1):1108.
Brice S, Almond H. Health professional digital capabilities frameworks: a scoping review. J Multidiscip Healthc. 2020;13:1375‐1390.
Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019;74(11):2087‐2102.
Anto A, Sousa‐Pinto B, Czarlewski W, et al. Automatic market research of mobile health apps for the self‐management of allergic rhinitis. Clin Exp Allergy. 2022;52(10):1195‐1207.
Dramburg S, Perna S, Di Fraia M, et al. Heterogeneous validity of daily data on symptoms of seasonal allergic rhinitis recorded by patients using the e‐diary AllergyMonitor(R). Clin Transl Allergy. 2021;11(10):e12084.
Tripodi S, Giannone A, Sfika I, et al. Digital technologies for an improved management of respiratory allergic diseases: 10 years of clinical studies using an online platform for patients and physicians. Ital J Pediatr. 2020;46(1):105.
Bastl K, Berger U, Kmenta M. Evaluation of pollen apps forecasts: the need for quality control in an eHealth service. J Med Internet Res. 2017;19(5):e152.
Bastl M, Bastl K, Dirr L, Berger M, Berger U. Variability of grass pollen allergy symptoms throughout the season: comparing symptom data profiles from the Patient's Hayfever diary from 2014 to 2016 in Vienna (Austria). World Allergy Organ J. 2021;14(3):100518.
Sousa‐Pinto B, Pfaar O, Bousquet J. Real‐life evidence in allergen immunotherapy: moving forward with mHealth apps. Allergol Select. 2023;7:47‐56.
Gerth van Wijk R, Klimek L, Pfaar O. Clinical endpoints in allergen immunotherapy: state of the art 2022. Allergol Select. 2023;7:39‐46.
Moore A, Preece A, Sharma R, et al. A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. Eur Respir J. 2021;57(6):2003103. doi:10.1183/13993003.03103-2020
Mosnaim GS, Stempel DA, Gonzalez C, et al. The impact of patient self‐monitoring via electronic medication monitor and Mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2021;9(4):1586‐1594.
Mosnaim GS, Stempel DA, Gonzalez C, et al. Electronic medication monitoring versus self‐reported use of inhaled corticosteroids and short‐acting beta(2)‐agonists in uncontrolled asthma. J Asthma. 2022;59(10):2024‐2027.
Sousa‐Pinto B, Anto A, Berger M, et al. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities. Clin Transl Allergy. 2022;12(11):e12208.
Sousa‐Pinto B, Sa‐Sousa A, Amaral R, et al. Assessment of the control of allergic rhinitis and asthma test (CARAT) using MASK‐air. J Allergy Clin Immunol Pract. 2022;10(1):343‐345. e2.
Hoffmann TM, Acar Sahin A, Aggelidis X, et al. “Whole” vs. “fragmented” approach to EAACI pollen season definitions: a multicenter study in six southern European cities. Allergy. 2020;75(7):1659‐1671.
Di Fraia M, Tripodi S, Arasi S, et al. Adherence to prescribed E‐diary recording by patients with seasonal allergic rhinitis: observational study. J Med Internet Res. 2020;22(3):e16642.
Pfaar O, Ankermann T, Augustin M, et al. Guideline on allergen immunotherapy in IgE‐mediated allergic diseases: S2K guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (OGAI), Swiss Society for Allergology and Immunology (SSAI), German dermatological society (DDG), German Society of Oto‐Rhino‐Laryngology, head and neck surgery (DGHNO‐KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German respiratory society (DGP), German professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, sleep and respiratory physicians (BdP), professional Association of German Dermatologists (BVDD). Allergol Select. 2022;6:167‐232. doi:10.5414/ALX02331E
Pfaar O, Sousa‐Pinto B, Devillier P, et al. Effects of allergen immunotherapy in the MASK‐air study: a proof‐of‐concept analysis. Allergy. 2021;76(10):3212‐3214.
Sousa‐Pinto B, Schunemann HJ, Sa‐Sousa A, et al. Comparison of rhinitis treatments using MASK‐air(R) data and considering the minimal important difference. Allergy. 2022;77(10):3002‐3014.
Sousa‐Pinto B, Azevedo LF, Sa‐Sousa A, et al. Allergen immunotherapy in MASK‐air users in real‐life: results of a Bayesian mixed‐effects model. Clin Transl Allergy. 2022;12(3):e12128.
Vieira RJ, Pham‐Thi N, Anto JM, et al. Academic productivity of Young people with allergic rhinitis: a MASK‐air study. J Allergy Clin Immunol Pract. 2022;10(11):3008‐3017. e4.
Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy. 2005;60(1):1‐3.
Bousquet J, Sousa‐Pinto B, Shamji MH, et al. Improvement of daily allergy control by sublingual immunotherapy: a MASK‐air(R) study. Clin Exp Allergy. 2023;53(8):854‐861.
Barker‐Tejeda TC, Bazire R, Obeso D, et al. Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics. Allergy. 2021;76(4):1199‐1212.
U.S. Food and Drug Administration. Patient‐focused drug development: collecting comprehensive and representative input. Final guidance document. Accessed March 28, 2024. https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/patient‐focused‐drug‐development‐collecting‐comprehensive‐and‐representative‐input
Verhoeven E, Rouadi P, Jaoude EA, et al. Digital tools in allergy and respiratory care. The World Allergy Organization Journal. 2022;15(7):100661.
Bousquet J, Anto JM, Bachert C, et al. ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice. Allergy. 2021;76(1):168‐190.
Sousa‐Pinto B, Jacome C, Pereira AM, et al. Development and validation of an electronic daily control score for asthma (e‐DASTHMA): a real‐world direct patient data study. Lancet Digit Health. 2023;5(4):e227‐e238.
Ferrer M, Lizano‐Barrantes C. Could an electronic tool to assess asthma control with a 1‐day timeframe be useful for clinical management? Lancet Digit Health. 2023;5(4):e177‐e178.
Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization consultation on severe asthma. J Allergy Clin Immunol. 2010;126(5):926‐938.
Bousquet J, Anto JM, Demoly P, et al. Severe chronic allergic (and related) diseases: a uniform approach–a MeDALL–GA2LEN–ARIA position paper. Int Arch Allergy Immunol. 2012;158(3):216‐231.
Bousquet J, Shamji MH, Anto JM, et al. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach – ARIA‐EAACI task force report. Allergy. 2023;78(7):1758‐1776.
Weldring T, Smith SM. Patient‐reported outcomes (PROs) and patient‐reported outcome measures (PROMs). Health Serv Insights. 2013;6:61‐68. doi:10.4137/HSI.S11093
Kluzek S, Dean B, Wartolowska KA. Patient‐reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27(3):153‐155.
Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69(7):854‐867.
Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. Allergy. 2017;72(10):1475‐1484.
Bousquet J, VandenPlas O, Bewick M, et al. The work productivity and activity impairment allergic specific (WPAI‐AS) questionnaire using Mobile technology: the MASK study. J Invest Allergol Clin Immunol. 2018;28(1):42‐44.
Bedard A, Anto JM, Fonseca JA, et al. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air((R)) app. Allergy. 2020;75(7):1672‐1688.
Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147‐S334.
Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158‐162.
Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62(4):367‐372.
Dramburg S, Perna S, Di Fraia M, et al. Prospective (e‐diary) vs retrospective (ARIA) measures of severity in allergic rhinoconjunctivitis: an observational compatibility study. Allergy. 2023;78(2):550‐553.
Matricardi PM, Sousa‐Pinto B, Dramburg S, Bousquet J. Beyond ARIA: will e‐diaries replace retrospective questionnaires in measuring the severity of allergic rhinitis in clinical research and daily practice? Clin Exp Allergy. 2023;53(10):1004‐1010.
European Medicines Agency. Commitee for medicinal products for human use (CHMP): Guideline on the Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases (CHMP/EWP/18504/2006). 2008. Accessed March 28, 2024. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf
Bahbah F, Gentil C, Sousa‐Pinto B, et al. Patient‐reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life. Allergy. 2023;78(4):1113‐1116.
Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta‐analyses. J Allergy Clin Immunol. 2011;128(4):791‐799 e6.
Bousquet J, Pfaar O, Agache I, et al. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021;11(4):e12014.
Pfaar O, Agache I, Bergmann KC, et al. Placebo effects in allergen immunotherapy‐an EAACI task force position paper. Allergy. 2021;76(3):629‐647.
Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8‐160.
Karatzas K, Riga M, Berger U, Werchan M, Pfaar O, Bergmann KC. Computational validation of the recently proposed pollen season definition criteria. Allergy. 2018;73(1):5‐7.
Pfaar O, Bastl K, Berger U, et al. Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen‐induced rhinoconjunctivitis – an EAACI position paper. Allergy. 2017;72(5):713‐722.
Tummon F, Arboledas LA, Bonini M, et al. The need for pan‐European automatic pollen and fungal spore monitoring: a stakeholder workshop position paper. Clin Transl Allergy. 2021;11(3):e12015.
Bousquet J, Anto JM, Annesi‐Maesano I, et al. POLLAR: impact of air POLLution on asthma and rhinitis; a European Institute of Innovation and Technology health (EIT health) project. Clin Transl Allergy. 2018;8:36.
Sousa‐Pinto B, Palamarchuk Y, Leemann L, et al. From MASK‐air and SILAM to CATALYSE (climate action To advance HeaLthY societies in Europe). J Invest Allergol Clin Immunol. 2024;34(1):12‐19.
Sofiev M, Palamarchuk Y, Bedard A, et al. A demonstration project of global Alliance against chronic respiratory diseases: prediction of interactions between air pollution and allergen exposure‐the Mobile airways sentinel NetworK‐impact of air POLLution on asthma and rhinitis approach. Chin Med J (Engl). 2020;133(13):1561‐1567.
Durham SR, Nelson HS, Nolte H, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy. 2014;69(5):617‐623.
Smolinska S, Popescu FD, Izquierdo E, et al. Telemedicine with special focus on allergic diseases and asthma‐status 2022: an EAACI position paper. Allergy. 2023;79:777‐792. doi:10.1111/all.15964
Matricardi PM, Dramburg S, Alvarez‐Perea A, et al. The role of mobile health technologies in allergy care: an EAACI position paper. Allergy. 2020;75(2):259‐272.